Arndt Hartmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4722543/publications.pdf

Version: 2024-02-01

158 papers 6,469 citations

34 h-index 72 g-index

164 all docs

164 docs citations

164 times ranked 10571 citing authors

#	Article	IF	Citations
1	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	10.7	1,327
2	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell, 2016, 30, 27-42.	16.8	486
3	Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine, 2020, 58, 102925.	6.1	369
4	STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut, 2020, 69, 1269-1282.	12.1	181
5	IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut, 2015, 64, 743-755.	12.1	151
6	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunology Research, 2019, 7, 923-938.	3.4	148
7	Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut, 2019, 68, 814-828.	12.1	146
8	Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Science Immunology, 2016, 1 , .	11.9	145
9	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	1.6	130
10	PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. European Journal of Cancer, 2016, 65, 52-60.	2.8	112
11	CLEC10A Is a Specific Marker for Human CD1c+ Dendritic Cells and Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion. Frontiers in Immunology, 2018, 9, 744.	4.8	110
12	Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Annals of Diagnostic Pathology, 2015, 19, 198-202.	1.3	102
13	Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. European Urology, 2020, 78, 256-264.	1.9	96
14	Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut, 2018, 67, 1328-1341.	12.1	77
15	PD-L1 assessment in urothelial carcinoma: a practical approach. Annals of Translational Medicine, 2019, 7, 690-690.	1.7	77
16	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	2.8	75
17	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European Urology, 2020, 78, 209-220.	1.9	66
18	CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer. Cancers, 2019, 11, 1398.	3.7	65

#	Article	IF	CITATIONS
19	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	1.9	61
20	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer, 2018, 18, 1051.	2.6	59
21	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 267-274.	2.8	58
22	EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death and Disease, 2020, 11, 147.	6.3	58
23	Enhanced Acid Sphingomyelinase Activity Drives Immune Evasion and Tumor Growth in Non–Small Cell Lung Carcinoma. Cancer Research, 2017, 77, 5963-5976.	0.9	55
24	Biofabrication of 3D Alginate-Based Hydrogel for Cancer Research: Comparison of Cell Spreading, Viability, and Adhesion Characteristics of Colorectal HCT116 Tumor Cells. Tissue Engineering - Part C: Methods, 2016, 22, 708-715.	2.1	54
25	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunology, Immunotherapy, 2018, 67, 403-412.	4.2	54
26	DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base. American Journal of Surgical Pathology, 2021, 45, 1682-1693.	3.7	47
27	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 508-524.	1.3	46
28	Non-professional phagocytosis: a general feature of normal tissue cells. Scientific Reports, 2019, 9, 11875.	3.3	45
29	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2019. 475. 599-608.	2.8	45
30	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy., 2020, 8, e000162.		45
31	FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncolmmunology, 2017, 6, e1256526.	4.6	44
32	Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 789-796.	2.8	42
33	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
34	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
35	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	2.5	40
36	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	2.9	39

#	Article	IF	CITATIONS
37	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. American Journal of Surgical Pathology, 2020, 44, e30-e46.	3.7	38
38	HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget, 2016, 7, 67360-67372.	1.8	38
39	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 2018, 80, 55-64.	2.0	36
40	Select hyperactivating NLRP3 ligands enhance the T $<$ sub $>$ H $<$ /sub $>$ 1- and T $<$ sub $>$ H $<$ /sub $>$ 17-inducing potential of human type 2 conventional dendritic cells. Science Signaling, 2021, 14, .	3.6	36
41	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. International Journal of Molecular Sciences, 2018, 19, 3396.	4.1	35
42	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology, 2019, 75, 865-875.	2.9	35
43	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 175, 617-625.	2.5	35
44	Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI. Journal of Biological Chemistry, 2020, 295, 4065-4078.	3.4	34
45	Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma. PLoS ONE, 2014, 9, e114345.	2.5	34
46	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	1.8	33
47	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	1.4	32
48	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 2018, 8, 14383.	3.3	32
49	Piwi-like 1 and 4 gene transcript levels are associated with clinicopathological parameters in renal cell carcinomas. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 686-690.	3.8	30
50	Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 2020, 130, 2509-2526.	8.2	29
51	Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist, 2019, 24, e1341-e1350.	3.7	28
52	Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. Journal of Cellular and Molecular Medicine, 2018, 22, 6238-6248.	3.6	27
53	Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity. Oncotarget, 2016, 7, 60383-60394.	1.8	27
54	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. Cancer Research, 2021, 81, 1552-1566.	0.9	26

#	Article	IF	CITATIONS
55	Endometriosis as a risk factor for ovarian or endometrial cancer â€" results of a hospital-based caseâ€"control study. BMC Cancer, 2015, 15, 751.	2.6	25
56	ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 547-552.	2.8	25
57	Primary signet ring stromal tumor of the testis: a study of 13 cases indicating their phenotypic and genotypic analogy to pancreatic solid pseudopapillary neoplasm. Human Pathology, 2017, 67, 85-93.	2.0	25
58	Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflammatory Bowel Diseases, 2018, 24, 35-44.	1.9	25
59	Genetic risk factors for ovarian cancer and their role for endometriosis risk. Gynecologic Oncology, 2017, 145, 142-147.	1.4	24
60	Sinonasal papillomas: A single centre experience on 137 cases with emphasis on malignant transformation and EGFR/KRAS status in "carcinoma ex papilloma― Annals of Diagnostic Pathology, 2020, 46, 151504.	1.3	24
61	Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. Cancers, 2020, 12, 763.	3.7	22
62	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World Journal of Urology, 2021, 39, 4011-4019.	2.2	22
63	Piwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients. Molecular Medicine, 2015, 21, 371-380.	4.4	21
64	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. Geburtshilfe Und Frauenheilkunde, 2017, 77, 667-678.	1.8	21
65	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIOâ€04 randomized phase 3 rectal cancer trial. International Journal of Cancer, 2019, 145, 2282-2291.	5.1	21
66	Validation of the â€~Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease. Journal of Crohn's and Colitis, 2021, 15, 1621-1630.	1.3	21
67	MET Amplification in Non-Small Cell Lung Cancer (NSCLC)â€"A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. Cancers, 2021, 13, 5023.	3.7	21
68	Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma. Molecular Oncology, 2019, 13, 1433-1449.	4.6	20
69	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Modern Pathology, 2022, 35, 836-849.	5.5	20
70	Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location. Annals of Diagnostic Pathology, 2015, 19, 221-225.	1.3	19
71	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. International Journal of Cancer, 2016, 139, 1967-1974.	5.1	19
72	<scp>FOXM</scp> 1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage <scp>pT</scp> 1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2019, 123, 187-196.	2.5	19

#	Article	IF	CITATIONS
73	Targeted sequencing of FH-deficient uterine leiomyomas reveals biallelic inactivating somatic fumarase variants and allows characterization of missense variants. Modern Pathology, 2020, 33, 2341-2353.	5.5	19
74	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. Journal of Cancer, 2017, 8, 323-331.	2.5	18
75	RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes. Cancers, 2020, 12, 64.	3.7	18
76	First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. World Journal of Urology, 2012, 30, 875-877.	2.2	17
77	Low Frequency of HNPCC-Associated Microsatellite Instability and Aberrant MMR Protein Expression in Early-Onset Bladder Cancer. American Journal of Clinical Pathology, 2014, 142, 634-639.	0.7	17
78	SMARCA4-deficient undifferentiated carcinoma of the ovary (small cell carcinoma, hypercalcemic) Tj ETQq0 0 0 2015, 19, 283-287.	rgBT /Ove 1.3	rlock 10 Tf 50 17
79	Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung. Scientific Reports, 2015, 4, 7396.	3.3	17
80	Infiltrative lamina propria invasion pattern as an independent predictor for cancerâ€specific and overall survival of instillation treatmentâ€naÃ⁻ve stageÂT1 highâ€grade urothelial bladder cancer. International Journal of Urology, 2018, 25, 442-449.	1.0	17
81	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. Cancers, 2020, 12, 2794.	3.7	17
82	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 248-256.e2.	1.9	16
83	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer, 2018, 18, 926.	2.6	16
84	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Translational Oncology, 2019, 12, 661-668.	3.7	16
85	Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget, 2017, 8, 67684-67695.	1.8	16
86	Long noncoding RNA <i>HOTAIR</i> is upregulated in an aggressive subgroup of gastrointestinal stromal tumors (GIST) and mediates the establishment of geneâ€specific DNA methylation patterns. Genes Chromosomes and Cancer, 2018, 57, 584-597.	2.8	15
87	Gpr126 (Adgrg6) is expressed in cell types known to be exposed to mechanical stimuli. Annals of the New York Academy of Sciences, 2019, 1456, 96-108.	3.8	15
88	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	2.5	15
89	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. Scientific Reports, 2020, 10, 15750.	3.3	15
90	High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 8407.	4.1	14

#	Article	IF	Citations
91	<scp>TFE3</scp> activation in a <scp><i>TSC1</i>â€altered</scp> malignant <scp>PEComa</scp> : challenging the dichotomy of the underlying pathogenic mechanisms. Journal of Pathology: Clinical Research, 2021, 7, 3-9.	3.0	14
92	Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease. International Journal of Clinical and Experimental Pathology, 2014, 7, 7419-31.	0.5	14
93	Easy performance of 6-color confocal immunofluorescence with 4-laser line microscopes. Immunology Letters, 2014, 161, 1-5.	2.5	13
94	Identification of miRNA-mRNA Modules in Colorectal Cancer Using Rough Hypercuboid Based Supervised Clustering. Scientific Reports, 2017, 7, 42809.	3.3	13
95	Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer. Cancers, 2020, 12, 446.	3.7	13
96	Mammographic density and prognosis in primary breast cancer patients. Breast, 2021, 59, 51-57.	2.2	13
97	Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?. International Journal of Molecular Sciences, 2020, 21, 8238.	4.1	12
98	WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. International Urology and Nephrology, 2017, 49, 431-437.	1.4	11
99	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 2018, 24, 3358-3365.	7.0	11
100	Regulatory T cells and cytotoxic T cells close to the epithelial–stromal interface are associated with a favorable prognosis. Oncolmmunology, 2020, 9, 1746149.	4.6	11
101	Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 157-167.	2.8	11
102	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers, 2021, 13, 1959.	3.7	11
103	Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 87.	4.1	11
104	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. Acta Radiologica, 2018, 59, 1406-1413.	1.1	10
105	A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 241-246.	2.8	10
106	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Research and Treatment, 2020, 184, 311-324.	2.5	10
107	Seizure-induced neuronal apoptosis is related to dysregulation of the RNA-edited GluR2 subunit in the developing mouse brain. Brain Research, 2020, 1735, 146760.	2.2	10
108	TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. Genes, 2021, 12, 230.	2.4	10

#	Article	IF	CITATIONS
109	The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression. Journal of Biological Chemistry, 2022, 298, 101699.	3.4	10
110	Low-grade Endometrioid Stromal Sarcoma of the Paratestis. American Journal of Surgical Pathology, 2018, 42, 695-700.	3.7	9
111	Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers, 2019, 11, 2029.	3.7	9
112	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. Modern Pathology, 2020, 33, 1433-1442.	5.5	9
113	Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. Scientific Reports, 2021, 11, 17981.	3.3	9
114	Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. PLoS ONE, 2020, 15, e0233422.	2.5	9
115	Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma. Human Pathology, 2016, 55, $101-107$.	2.0	8
116	The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a siteâ€dependent manner in gastrointestinal stromal tumours. International Journal of Cancer, 2017, 141, 2296-2304.	5.1	8
117	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e629-e642.	1.9	8
118	TERTpromoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder. Histopathology, 2020, 77, 949-962.	2.9	8
119	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. Cancers, 2021, 13, 2327.	3.7	8
120	Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer. Bladder Cancer, 2017, 3, 173-180.	0.4	7
121	Uncovering Hereditary Tumor Syndromes: Emerging Role of Surgical Pathology. Seminars in Diagnostic Pathology, 2018, 35, 154-160.	1.5	7
122	DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma. Human Pathology, 2019, 84, 1-7.	2.0	7
123	Digital pathology imaging and computer-aided diagnostics as a novel tool for standardization of evaluation of aganglionic megacolon (Hirschsprung disease) histopathology. Cell and Tissue Research, 2019, 375, 371-381.	2.9	7
124	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Journal of Clinical Pathology, 2023, 76, 126-132.	2.0	7
125	Renal cell tumor with sex-cord/gonadoblastoma-like features: analysis of 6 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 349-358.	2.8	7
126	The synergism of spatial metabolomics and morphometry improves machine learningâ€based renal tumour subtype classification. Clinical and Translational Medicine, 2022, 12, e666.	4.0	7

#	Article	IF	Citations
127	Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?. Bladder Cancer, 2017, 3, 31-34.	0.4	6
128	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology, 2021, 157, 93-101.	1.0	6
129	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment. Cancers, 2021, 13, 4718.	3.7	6
130	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) Journal of Clinical Oncology, 2020, 38, TPS5103-TPS5103.	1.6	6
131	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prEvalence in pregNAncy and at biRth In FrancOnia). Geburtshilfe Und Frauenheilkunde, 2022, 82, 226-234.	1.8	6
132	Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. European Urology, 2022, 81, 606-614.	1.9	6
133	Isolation of Human Endothelial Cells from Normal Colon and Colorectal Carcinoma - An Improved Protocol. Journal of Visualized Experiments, 2018, , .	0.3	5
134	Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. Cancers, 2020, 12, 2639.	3.7	5
135	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 473.	2.5	5
136	Molecular Characterization of Muellerian Tumors of the Urinary Tract. Genes, 2021, 12, 880.	2.4	5
137	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers, 2021, 13, 5577.	3.7	5
138	Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes. International Journal of Molecular Sciences, 2021, 22, 13108.	4.1	5
139	Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TlLs) as tumor-host antagonists. International Journal of Colorectal Disease, 2021, 36, 2497-2510.	2.2	4
140	The Prognostic and Predictive Significance of Tumor-Infiltrating Memory T Cells Is Reversed in High-Risk HNSCC. Cells, 2022, 11, 1960.	4.1	4
141	Asymmetric Omphalopagus in a Triplet after In Vitro Fertilization: A Rare Case of Conjoined Twinning. Case Reports in Pediatrics, 2018, 2018, 1-5.	0.4	3
142	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	1.8	3
143	Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Seminars in Diagnostic Pathology, 2021, 38, 152-162.	1.5	3
144	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments. International Journal of Molecular Sciences, 2021, 22, 10433.	4.1	3

9

#	Article	IF	CITATIONS
145	A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial) Journal of Clinical Oncology, 2020, 38, 6519-6519.	1.6	3
146	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225–31. European Urology, 2021, 80, e17-e18.	1.9	2
147	Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: an observational research study. BMC Pediatrics, 2022, 22, 192.	1.7	2
148	Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial Journal of Clinical Oncology, 2022, 40, 6064-6064.	1.6	2
149	BRAF mutation testing in melanoma: results from a German observational multicenter study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 71-78.	2.8	1
150	Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. Scientific Reports, 2020, 10, 20472.	3.3	1
151	Risk of penile tumor development in Caucasian individuals is independent of the coding variant rs7208422 in the TMC8 (EVER2) gene. Molecular and Clinical Oncology, 2021, 15, 267.	1.0	1
152	DMBT1 expression and neutrophil-to-lymphocyte ratio during necrotizing enterocolitis are influenced by impaired perfusion due to cardiac anomalies. Molecular and Cellular Pediatrics, 2022, 9, 1.	1.8	1
153	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	1.4	0
154	Surgical and oncological outcome after extended lymph node dissection for carcinoma of the stomach and the esophagogastric junction: a retrospective analysis from an experienced single center. Archives of Medical Science, 2024, 20, 124-132.	0.9	0
155	Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. , 2020, 15, e0233422.		0
156	Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. , 2020, 15, e0233422.		0
157	Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. , 2020, 15, e0233422.		0
158	Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues. , 2020, 15, e0233422.		0